Breakthrough ALS drug shows promise for rare inherited form of the disease

Otsuka Pharmaceutical and Ionis Pharmaceuticals announced that their experimental drug, ulefnersen, successfully met the primary endpoint of a late-stage clinical trial in patients with FUS-ALS — a rare, inherited form of amyotrophic lateral sclerosis caused by mutations in the FUS protein. This is a significant milestone, as there are currently no approved therapies that specifically target the genetic cause of FUS-ALS.

The drug, designed to reduce production of the disease-causing FUS protein, improved both function and survival compared to placebo. It also reduced biomarkers associated with nerve cell damage and delayed disease progression. The safety profile was encouraging, with most adverse events reported as mild or moderate.

Key Takeaways:

• Ulefnersen is the first drug to show efficacy specifically targeting the genetic cause of FUS-ALS
• Otsuka and Ionis plan to pursue accelerated approval pathways with the FDA and global health authorities
• A global early access program has been launched for eligible FUS-ALS patients who cannot participate in clinical trials

Why it matters: FUS-ALS is a devastating condition that progressively robs patients of the ability to move, speak, swallow, and breathe. With no targeted treatments currently available, ulefnersen could represent a critical first step toward a disease-modifying therapy for this underserved patient population.